Why most people may be getting the wrong cholesterol test

We often blindly rely on our medical reports, but according to experts, a recent study believes that millions of Americans roll up their sleeves every year for a standard blood test to check their LDL, the infamous "bad" cholesterol.

However, a recent study from Northwestern Medicine suggests we might be leaning on the wrong metric. As per a report on ScienceDaily, wherein a study around this matter was published in JAMA, the research reveals that measuring apolipoprotein B (apoB) is actually much more effective at pinpointing who needs aggressive treatment to prevent heart attacks and strokes.Why ApoB Beats Standard LDL TestsFor decades, doctors have used LDL and non-HDL levels to decide when to start or ramp up cholesterol medications like statins.

While these tests are helpful, they don't tell the whole story.According to study lead author Ciaran Kohli-Lynch, an assistant professor at Northwestern University, apoB is a superior risk predictor because it counts the actual number of harmful particles in your blood. Traditional tests measure the amount of cholesterol, but apoB measures the vehicles carrying it—the very particles that get trapped in artery walls and build up into dangerous plaque.

The Hurdle of Extra TestingDespite the mounting evidence favoring apoB, you probably haven't had one done at your annual physical. Right now, measuring apoB usually requires an extra blood test outside of the standard cholesterol panel. This adds both an extra step for the patient and an extra charge to the bill. This hurdle led the research team to ask a critical question: Is the extra cost of apoB testing actually worth it?Testing the StrategiesTo find out, the researchers built a computer simulation tracking 250,000 U.S. adults. All participants were eligible for statin therapy but did not have existing heart disease. The team simulated three different lifetime treatment strategies based on different targets:LDL cholesterol: Goal of less than 100 mg/dLNon-HDL cholesterol: Goal of less than 118 mg/dLApoB: Goal of less than 78.7 mg/dLIf a simulated patient didn't hit their target, their treatment was stepped up—first with stronger statins, and then by adding a medication called ezetimibe.Better Health Outcomes, Smart SpendingThe simulation tracked life expectancy, quality of life, healthcare costs, and heart events. The results were clear: the apoB strategy consistently outperformed the others. Using apoB to guide treatment prevented more heart attacks and strokes, improved overall health outcomes, and did so at a price point that represents excellent value for the U.S. healthcare system.Shift in Heart CareDoctors have ways to lower cholesterol than they ever have before. The American Heart Association and other medical groups have rules that say people should start taking cholesterol medicine when they are younger. If we have a way to track cholesterol like apoB then doctors can give patients the right amount of help at the right time. This is very important for heart care and the people who need it. The new tools and rules for heart care are a shift in the way doctors treat people with heart problems. Heart care is. Doctors are getting better at helping people with heart problems especially with the new cholesterol tools.